Nautilus Biotechnology, Inc. expected to post a loss of 14 cents a share - Earnings Preview

Nautilus Biotechnology

Yesterday 13:45

Nautilus Biotechnology, Inc. NAUT.OQ NAUT.O is expected to  show a rise in quarterly revenue when it reports  results on October 27 for the period ending September 30 2026
The Seattle Washington-based  company is expected to report revenue of $206.25 thousand, according to the mean estimate from 4 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Nautilus Biotechnology, Inc. is for a loss of 14 cents per share. 
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Nautilus Biotechnology, Inc. is $4.00, about 53.8% above its last closing price of $2.60
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Jun. 30 2026
-0.13
-0.13
-0.11
Beat
18.5
Mar. 31 2026
-0.14
-0.14
-0.12
Beat
17.2
Dec. 31 2025
-0.14
-0.11
Beat
21.4​
Sep. 30 2025
-0.15
-0.11
Beat
26.7
​​Jun. 30 2025
-0.15
-0.12
Beat
22.6
Mar. 31 2025
-0.14
-0.15
-0.13
Beat
11.3​
Dec. 31 2024
-0.16
-0.16
-0.14
Beat
13.6
Sep. 30 2024
-0.16
-0.16
-0.13
Beat
21.2
This summary was machine generated October 23 at 12:45 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)